低水溶性之抗癌藥物camptothecin (CPT)在人體血液之pH值及血液中血清白蛋白的存在下，易轉化成抗癌活性較小但細胞毒性大的carboxylate結構，造成嚴重之副作用，使臨床應用上效果不佳，因此考慮以微脂粒為藥物載體，避免CPT在人體生理條件下水解以及在血液中與血清白蛋白結合。本研究利用以egg yolk phosphatidylcholine （EPC）及 hydrogenated soybean phosphatidylcholine （HSPC）組成微脂粒為藥物載體包覆CPT，並添加膽固醇及雙十六碳鏈磷酸鹽（dicetyl phosphate，DCP），以期增加微脂粒之穩定度及包覆藥物之效率。
在實際以微脂粒包覆CPT之前，為瞭解脂質與CPT間的交互作用，本研究利用Langmuir trough之單分子層實驗，量測不同莫耳比之HSPC/DCP、DCP/CPT、EPC/DCP、DCP/CPT、HSPC/CPT及EPC/CPT混合單分子層於37℃磷酸緩衝溶液（pH = 7.4）/空氣界面上之界面性質。從過剩自由能之分析，HSPC/DCP 100/80 (莫耳/莫耳)及EPC/DCP 100/40 (莫耳/莫耳) 分別為HSPC/DCP、EPC/DCP系統最穩定之組成比例。此外，原本未有明顯界面性質之CPT，會與DCP、HSPC、EPC作用而改變脂質之界面行為，尤其與DCP間之交互作用最為明顯，由□-A等溫線圖發現，CPT與DCP可以等莫耳比形成混合單分子層，而與EPC或HSPC則最多僅能形成莫耳比EPC/CPT 100/8.8及HSPC/CPT 100/4.4之混合單分子層。

在微脂粒研究中，微脂粒組成為EPC/DCP 100/40 (莫耳/莫耳)，可包覆CPT高達CPT/ EPC 8.8/100 (莫耳/莫耳)，為包覆藥物量最高之配方。此外本研究在37℃下分別對EPC/DCP 100/40 (莫耳/莫耳) 、EPC/DCP 100/20 (莫耳/莫耳)及HSPC/DCP 100/20 (莫耳/莫耳)三微脂粒系統進行藥物釋放的實驗，結果發現EPC/DCP系統與HSPC/DCP系統之微脂粒有類似之藥物釋放行為。

Alsina M. A., Mestres C., Rabanal F., Busquets M. A., Reig F., Miscibility of HBV peptides and dipalmitoylphosphatidylcholine in monolayers. Langmuir, 9, 1129-1133 (1993)
Berges D. A., Taggart J. J., Water soluble camptothecin analogs. United State Patent, patent number 5663177
Birdi K. S., Lipid and biopolymer monolayers at liquid interfaces. Plenum Press, New York (1989)
Blume A., A comparative study of the phase transitions of phospholipids bilayers and monolayers. Biochim. Biophys. Acta, 557, 32-44 (1979)
Bruke T. G., Mishra A. K., Wani M. C., Wall M. E., Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry, 32, 5352-5364 (1993)
Burke T. G., Gao X., Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcoline. J. Pharma. Sci., 83, 967-969 (1994)
Burke T. G., Mi Z., The structural basis of camptothecin interactions with human serum albumin: impact on drug stability, J. Med. Chem., 37, 40-46 (1994)
Bürner H., Benz R., Gimmler H., Hartung W., Stillwell W., Abscisic acid-lipid interactions: a phospholipids monolyer study. Biochim. Biophys. Acta, 1150, 165-172 (1993)
Carmona-Ribeiro A. M., Hix S., pH effects on properties of dihexadecyl phosphate vesicles. J. Phys. Chem., 95, 1812-1817 (1991)
Cortesi R., Esposito E., Maietti A., Menegatti E., Nastruzzi C., Formulation study for the antitumor drug camptothecin: liposomes, micellar solutions and a microemulsion. Inter. J. Pharma., 159, 95-103 (1997)
Florence A. T., Liposomes rational design. Marcel Dekker Inc. (1999)
Gopal A., Lee K. Y. C., Morphology and collapse transition in binary phospholipids monolayers. J. Phys. Chem. B, 105, 10348-10354 (2001)
Gottlieb J. A., Guarino A. M., Call J. B., Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother. Rep., 54, 461-470 (1970)
Grit M., Underberg W. J. M., Crommelin D. J. A., Hydrolysis of saturated soybean phosphatidylcholine in aqueous liposome dispersions. J. Pharma. Sci., 82 (4), 362-366 (1993)
Hammarström L., Velikian I., Karlsson G., Edwards K., Cryo-TEM evidence: sonication of dihexadecyl phosphate does not produce closed bilayers with smooth curvature. Langmuir, 11(2), 408-410 (1995)
Hertzberg R. P., Caranfa M. J., Holden K. G., Jakas D. R., Gallagher G., Mattern M. R., Mong S. M., Bartus J. O., Johnson R. K., Kingsbury W. D., Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem., 32, 715-720 (1989)
Hsiang Y. H., Hertzberg R. P., Hecht S., Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Bio. Chem., 260, 14873 (1985)
Izumi K., Seiichi A., Hidekatsu M., Atsushi S., Phosphatidylcholine monolayers observed with Brewster angle microscopy and □-A isotherms. Thin Solid Films, 393, 80 (2001)
Jones M. N., Chapman D., Micelles, monolayers, and biomembranes. Wiley-Liss, Inc.(1995)
Kaganer V. M., Möhwald H., Dutta P., Structure and phase transitions in Langmuir monolayers. Rev. Mod. Phys., 71, 779-819 (1999)
Koshkina N. V., Gillbert B. E., Waldrep J. C., Knight A. S. V., Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice. Cancer Chemother. Pharmacol., 44, 187-192 (1999)
Lasic D. D., Novel applications of liposomes. Trends Biotechnol., 16, 307-321 (1998)
Mi Z., Burke T. G., Marked interspecies variations concerning the interactions of camptothecin with serum albumins: a frequency-domain fluorescence spectroscopic study. Biochemistry, 33, 12540-12545 (1994)
Mitchell M. L., Dluhy R. A., In situ FT-IR investigation of phospholipids monolayer phase transitions at air-water interface. J. Am. Chem. Soc., 110, 712-718 (1988)
Miyasaka T., Sawada S., Nokata K., Sugino E., Mutai M., Camptothecin derivatives and process for preparing same. United State Patent, patent number 4604463
Moertel C. G., Schutt R. J., Reitemeier R. J., Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep., 56, 95 (1972)
Muggia F. M., Creaven P. J., Hansen H. H., Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother. Rep., 56, 515 (1972)
New R. R. C., Liposomes: a practical approach. Oxford University Press (1990)
Rana F. A., Mautone A. J., Dluhy R. A., Surface chemistry of binary mixtures of phospholipids in monolayers. Infrared studies of surface composition at varying surface pressure in pulmonary surfactant model system. Biochemistry, 32, 3169-3177 (1993)
Rocio Garcia-Carbonero, Supko J. G., Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin. Cancer Res., 8, 641 (2002)
Subramanian D., Muller M. T., Liposomal encapsulation increase the activity of the topoisomerase I inhibitor topotecan. Oncol. Res., 7(9), 461-469 (1995)
Sugerman S. M., Zou Y. Y., Wasan K., Poirot K., Kumi R., Reddy S., Perez-soler R., Lipid-complexed camptothecin: formulation and initial biodistribution and antitumor activity studies. Cancer Chemother. Pharmacol., 37, 531-538 (1996)
Wall M. E., Wani M. C., Cook C. E., Plant anti-tumor agents. 1. The isolation and structure of camptothecin, a novel alkaloid leukemia and tumor inhibitor from Camptotheca acuminates. J. Am. Chem. Soc., 88, 3888-3890 (1966)
Weis R. M., McConnell H. M., Cholesterol stabilizes the crystal-liquid interface in phospholipids monolayers. J. Phys. Chem., 89, 4453-4459 (1985)
Yang S. C, Lu L. F., Cai Y., Zhu J. B., Liang B. W., Yang C. Z., Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Control. Rel., 59, 299-307 (1999)
Yasuyuki S., Sachiyo H., Sadao H., Effective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38. Jap. J. Cancer Res. : Gann, 90, 226-232 (1999)
Yasuyuki S., Sadzuda H., Sadao H., Effect of liposomal- ization on the antitumor activity, side-effect and tissue distribution of CPT-11. Cancer Letters, 127, 99-106 (1998)
Yoshiaki M., Hiraku O., Akinobu K., Harumi H., Akinobu M., Yoshiharu M., Pharmacokinetics of prolonged-released CPT-11-loaded microspheres in rats. J. Control. Rel., 66, 159-175 (2000)